Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02603952 · ClinicalTrials.gov registry record · Phase 1
A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 126
- Enrollment target
NCT02603952 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 126 participants.
The verdict
NCT02603952, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 126 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate safety and tolerability of a single dose of MEDI8852 when given with oseltamivir, the safety and tolerability of oseltamivir alone, and the safety and tolerability of a single dose of MEDI8852 alone in adult participants with acute, uncomplicated influenza caused by Type A strains.
Interventions
- DRUG Placebo
- DRUG Oseltamivir
- DRUG MEDI8852
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2015-12-07 |
| Est. Completion | 2016-12-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02603952
The ClinicalTrials.gov registry entry for NCT02603952 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02603952 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02603952 about?
NCT02603952 is a clinical study titled "A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza". The purpose of this study is to evaluate safety and tolerability of a single dose of MEDI8852 when given with oseltamivir, the safety and tolerability of oseltamivir alone, and the safety and tolerability of a single dose of MEDI8852 alone in adult participants with acute, uncomplicated influenza ca...
What is the current status of trial NCT02603952?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 126 participants. The study started on 2015-12-07. Estimated completion is 2016-12-09.
What interventions are being tested in trial NCT02603952?
The interventions under investigation include: Placebo (DRUG), Oseltamivir (DRUG), MEDI8852 (DRUG).
Who is sponsoring clinical trial NCT02603952?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.